Page 16 - AN-4-3

Advanced Neurology Stem cell therapy in stroke treatment: Advances and prospects

This problem can be addressed with MSCs, as they possess
References 91 91 92 93 multipotency and a high regeneration capacity. However,
it is still too early to conclude whether MSC therapy
can improve outcomes in stroke cases. A recent meta-
95
Abbreviations: MSCs: Mesenchymal stem cells; mRS: Modified Rankin scale; NIHSS: National Institutes of Health Stroke Scale; MRI: Magnetic resonance imaging; BM: Bone marrow;
analysis in the field of cardiology showed that adult bone-
marrow transplantation when compared to conventional
Primary outcomes NIHSS, ESS, mRS NIHSS, mRS mRS, NIHSS NIHSS, mRS, BI therapy, improved infarct size, remodeling, and left
ventricular function in individuals with ischemia-related
cardiovascular disease. This result was based on data from
96
50 studies involving 2625 patients. These studies utilized
echocardiograms and included long-term follow-ups for
patients receiving stem cell transplants. The first effective
Time point from onset of infusion 6 months – 5 years 6 months – 5 years 1 – 3 days 2 – 4 weeks cell transplantation – took 60 years to develop. Therefore,
stem cell treatment in hematology – hematopoietic stem
97
developing important and innovative treatments will
necessitate ongoing collaboration between researchers and
medical professionals involved in clinical trials. The basic
principles of stem cell therapy will be better understood
through further advancements in both laboratory research
Dose 3 – 8×110 6 3 – 8×10 6 10 million cells/kg b. wt. 1×10 6 and clinical settings, ultimately improving the therapeutic
efficacy of cell-based treatments for stroke cases.

9. Conclusion
FMA: Fugl–Meyer assessment; BMSCs: Bone marrow stem cells; b. wt.: Body weight; ESS: European stroke scale.

significant problems still need to be fixed to fully harness
its potential. In addition to improving delivery methods
Route of administration Intracranial Stereotactic Intravenous Intra-arterial MNCs: Mononuclear cells; BM-MNCs: Bone marrow-mononuclear cells; BI: Barthel index; CT: Computed tomography; PET: Positron emission tomography; DTI: Diffusion tensor imaging; Despite stem cell treatment for stroke shows great promise,
and developing protocols to ensure patient safety and
efficacy, the present study aims to enhance cell survival
and integration into ischemic brain tissue. Further
understanding of the therapeutic potential and mechanisms
of action of various types of stem cells is expected to lead
Interventional types BM-MNCs BM-MNC to better treatment outcomes for stroke patients. Together,
basic research and clinical practice will be crucial in
overcoming present challenges and transforming these
CD34+
PBSCs
findings into effective therapies, ultimately improving
the quality of life and recuperation of stroke survivors.
Furthermore, reaching this objective will require research
into innovative strategies. By investigating cutting-edge
treatments, including neuroprotective drugs, robotic

can better address the various needs of stroke patients and
Cell types Peripheral cells PBSCs Bone marrow harvest Posterior iliac crest rehabilitation, and individualized treatment programs, we
maximize their chances of recovery. Collaboration among
researchers, physicians, and patients will pave the way for
Sample size 15/15 15/15 25/30 12/18 translating these developments into effective therapeutic
applications, which will transform the future of stroke
rehabilitation.
Table 2. (Continued) Country/Region, year Taiwan region, 2014 China, 2014 USA, 2019 Egypt, 2016 Acknowledgments

None.

Funding

Volume 4 Issue 3 (2025) 10 None. doi: 10.36922/an.5582